Ansell SM et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. N Engl J Med 2022;387(4):310-20. Abstract
Banerjee S et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. ESMO 2022;Abstract 529MO.
Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract
Coleman RL et al. Overall survival results from the ARIEL3: A phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. IGCS 2022;Abstract O003/557.
Cortés J et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med 2022;386(12):1143-54. Abstract
DiSilvestro P et al. Overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib in the SOLO1/GOG 3004 trial. IGCS 2022;Abstract S003/1610.
Gaillard S et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021;163(2):237-45. Abstract
Gonzalez-Martin A et al. PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety. IGCS 2022;Abstract S005/1753.
Hamanishi J et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: Open-label, randomized trial in Japan (NINJA). J Clin Oncol 2021;39(33):3671-81. Abstract
Hardesty MM et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 2022;166(2):219-29. Abstract
Hong P et al. Tumor treating fields: A comprehensive overview of the underlying molecular mechanism. Expert Rev Mol Diagn 2022;22(1):19-28. Abstract
Indini A et al. Immune-checkpoint inhibitors in platinum-resistant ovarian cancer. Cancers (Basel) 2021;13(7):1663. Abstract
Leath CA III et al. Overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3. IGCS 2022;Abstract LB001/1731.
Li N et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): A randomized, double-blind, placebo-controlled, phase 3 trial. SGO 2022;Abstract LBA5.
Lonial S et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 2021;127(22):4198-212. Abstract
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract
Monk BJ et al. ATHENA-MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy vs placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. IGCS 2022;Abstract S001/1608.
Ning L et al. Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): A multicenter, randomized, double-blind, placebo-controlled phase III trial. J Clin Oncol 2022;40(22):2436-46. Abstract
O’Malley DM et al. Efficacy analysis by disease risk subgroup for the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ova-45) evaluating rucaparib maintenance treatment in patients with newly diagnosed ovarian cancer. IGCS 2022;Abstract O026/560.
Oaknin A et al. Characterization of extended treatment benefit from three phase I and III clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. ESGO 2022;Abstract 2022-RA-660-ESGO.
Oza AM et al. Overall survival results from the phase 3 ARIEL4 study of rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA 1/2 mutation. IGCS 2022;Abstract S004/461.
Poveda A et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):620-31. Abstract
Pujade-Lauraine E et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): An open-label, three-arm, randomised, phase 3 study. Lancet Oncol 2021;22(7):1034-46. Abstract
Randall LM et al. MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). ASCO 2022;Abstract 5573.
Ray-Coquard I et al. Final overall survival results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer. IGCS 2022;Abstract S002/1609.
Redondo A et al. Maintenance olaparib rechallenge in patients with ovarian cancer previously treated with a PARP inhibitor: Patient-reported outcomes from the phase IIIb OReO/ENGOT-ov-38 trial. IGCS 2022;Abstract O025/522.
Richardson DL et al. Comparison of NaPi2b expression from paired tissue samples in a clinical study of upifitamab rilsodotin (UpRi; XMT-1536) supports a strategy of testing in archival material. IGCS 2022;Abstract 425.
Ronny D et al. Evaluation of NaPi2b expression in a well-annotated longitudinal tissue series of ovarian serous carcinomas. IGCS 2022;Abstract 408.
Rosenberg JE et al. Study EV-103 cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). ESMO 2022;Abstract LBA73.
Selle F et al. OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. ASCO 2022;Abstract 558.
Shams S, Patel CB. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]). J Mol Cell Bio 2022;[Online ahead of print]. Abstract
Steuer CE et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations. ASCO 2022;Abstract 9017.
Tarantino P et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 2022;72(2):165-82. Abstract
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Vergote I et al. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol 2018;150(3):471-7. Abstract
Yurkovetskiy AV et al. Dolaflexin: A novel antibody-drug conjugate platform featuring high drug loading and a controlled bystander effect. Mol Cancer Ther 2021;20(5):885-95. Abstract